Date: 2013-06-12
Type of information:
phase: 2
Announcement: presentation of Phase 2 data on brodalumab being investigated for the treatment of psoriatic arthritis at the 2013 European League Against Rheumatism (EULAR) Annual Meeting in Madrid, June 12-15, 2013.
\"Efficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis\"
Company: Amgen (USA) AstraZeneca (UK)
Product: brodalumab
Action mechanism: Brodalumab (AMG 827) is a human monoclonal antibody that binds to and blocks signaling via the IL-17 receptor.
Disease:
Therapeutic area: Autoimmune diseases
Country:
Trial details:
Latest
news: * On June 12, 2013, Amgen and AstraZeneca have announced that they will present data from a Phase 2 study evaluating brodalumab, a human monoclonal antibody targeting the IL-17 receptor, being investigated for the treatment of psoriatic arthritis at the 2013 European League Against Rheumatism (EULAR) Annual Meeting in Madrid, June 12-15, 2013. Based on the Phase 2 results, the companies intend to advance brodalumab into Phase 3 clinical studies for the treatment of psoriatic arthritis in 2014. In addition to psoratic arthritis, brodalumab is currently being investigated for the treatment of psoriasis (Phase 3) and asthma (Phase 2).
Last year, Amgen and AstraZeneca have concluded an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen\'s clinical inflammation portfolio, including brodalumab.
